Clinical Trial

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is hypothesized that CBD will improve symptoms, neurocognition, markers of inflammation and eating behaviors. Importantly, moderators and mediators of the CBD effects will be explored.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-05-27; most recent amendment 2026-01-07.
Status change: Not Yet Recruiting → Recruiting 2021-06-04
Trial Details
NCT Number NCT04411225
Lead Sponsor University of California, San Diego
Collaborators: Center for Medicinal Cannabis Research
Conditions Early Psychosis
Enrollment 120 participants
Start Date 2022-06-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-08